An observational study in Familial Hypercholesterolemia and Genetic Disorder, sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi). Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hyperlipoproteinemia Type II with a site in Italy — 4 open to participants now, 4 under way, 2 of them phase 3. Hyperlipoproteinemia Type II · Italy.
Among the 19 studies in Hyperlipoproteinemia Type II with a site in Italy, this one is one of 2 that started in 2015, is one of 4 observational ones, and was the 18th registered.
251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →4 of the 19 studies in Hyperlipoproteinemia Type II with a site in Italy are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 20 more countries
Ages 6–11
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 23 more countries
Ages 2–100
Federico II University · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 12
First in 2003; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 770 across 64 observational studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 15 interventional studies, 3,208 across the 4 observational. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 10 most frequent:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Hyperlipoproteinemia Type II with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).
What does the study do?
It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures.
It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments.
It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments.
It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes.
Who can participate?
The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia.
More than 50 centres throughout Italy are involved, making the study accessible to many.
What does participation entail?
Participants will continue with their normal clinical practice.
Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures.
For some, further evaluations, such as ultrasounds, may be required to better study their condition.
The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments.
Subjects with molecular or clinical diagnosis of genetic dyslipidemia of any age or sex.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lipid profile of patients with genetic dyslipidemia
Lipid profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * LDL cholesterol (mg/dL) * Total cholesterol (mg/dL) * HDL cholesterol (mg/dL) * Triglycerides (mg/dL) * Lipoprotein (a) (mg/dL), if available
Time frame: At baseline and through study completion up to 20 years
Genetic profile of patients with genetic dyslipidemia
Genetic profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * Prevalance (%) of patients with pathogenic/likely pathogenic variants on candidate genes * Prevalance (%) of patients with variants of uncertain significance (VUS) on candidate genes * Distribution (%) of more common variants
Time frame: At baseline evaluation
Plan to share: No
Started Aug 2015 (actual). Primary completion is estimated for Dec 2036, 256 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Sep 2026 → Dec 2036 and completion Sep 2026 → Dec 2036.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)